Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects...

od Pearlman David S, Miller S David, LaForce Craig, Oh Chad K, Parker Joseph M, Le Chenxiong, Robbie Gabriel J, White Wendy I, White Barbara, Molfino Nestor A
Izdano 2011-02-01

Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects...

od Parker, Joseph M, Oh, Chad K, LaForce, Craig, Miller, S David, Pearlman, David S, Le, Chenxiong, Robbie, Gabriel J, White, Wendy I, White, Barbara, Molfino, Nestor A
Izdano 2011

The impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort study

od Schmidt, Sigrun Alba Johannesdottir, Johansen, Martin Berg, Olsen, Morten, Xu, Xiao, Parker, Joseph M, Molfino, Nestor A, Lash, Timothy L, Sørensen, Henrik Toft, Christiansen, Christian Fynbo
izdano v BMJ Open (2014)

Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency

od Shapiro, Amy D., Nakar, Charles, Parker, Joseph M., Albert, Gary R., Moran, John E., Thibaudeau, Karen, Thukral, Neelam, Hardesty, Brandon M., Laurin, Pierre, Sandset, Per Morten
izdano v Blood (2018)

Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis

od Khalil, Nasreen, Manganas, Helene, Ryerson, Christopher J., Shapera, Shane, Cantin, Andre M., Hernandez, Paul, Turcotte, Eric E., Parker, Joseph M., Moran, John E., Albert, Gary R., Sawtell, Renata, Hagerimana, Aline, Laurin, Pierre, Gagnon, Lyne, Cesari, Frank, Kolb, Martin
izdano v Eur Respir J (2019)